Conmed (CNMD) Stock Price
Conmed Price
Over the last 19 years Conmed grew revenue by 4.0% annually, reaching 1.37 B USD. Earnings per share have grown at 0.3% per year over the last 18 years. For Conmed, the net margin of 3.4% is down versus 6.2% a few years ago. At today's price the dividend yield works out to roughly 1.22%. The payout ratio is around 40% of earnings. The consensus 12-month price target for Conmed is 43.86 USD, about 10.7% below where the stock trades today. Of 12 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 54% above its 52-week low.
Conmed stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Conmed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Conmed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Conmed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Conmed Price |
|---|---|
| 9/1/2026 | 49.12 USD |
| 8/31/2026 | 49.85 USD |
| 8/30/2026 | 50.03 USD |
| 8/28/2026 | 50.31 USD |
| 8/27/2026 | 50.62 USD |
| 8/26/2026 | 50.48 USD |
| 8/25/2026 | 51.13 USD |
| 8/24/2026 | 52.20 USD |
| 8/21/2026 | 51.07 USD |
| 8/20/2026 | 51.38 USD |
| 8/19/2026 | 51.42 USD |
| 8/18/2026 | 50.64 USD |
| 8/14/2026 | 50.41 USD |
| 8/13/2026 | 49.82 USD |
| 8/12/2026 | 49.48 USD |
| 8/11/2026 | 49.58 USD |
| 8/10/2026 | 49.82 USD |
| 8/7/2026 | 49.12 USD |
| 8/6/2026 | 49.77 USD |
| 8/5/2026 | 49.76 USD |
| 8/4/2026 | 50.68 USD |
| 8/3/2026 | 51.86 USD |
| 7/31/2026 | 46.30 USD |
| 7/30/2026 | 46.98 USD |
| 7/29/2026 | 43.89 USD |
| 7/27/2026 | 43.67 USD |
| 7/23/2026 | 41.27 USD |
| 7/22/2026 | 42.00 USD |
| 7/21/2026 | 41.88 USD |
| 7/20/2026 | 43.45 USD |
Conmed Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.73 | 0.72 | 0.76 | 0.80 | 0.86 | 0.96 | 0.86 | 1.01 | 1.05 | 1.24 | 1.31 | 1.37 | 1.37 | 1.43 | 1.51 | 1.59 |
| -2.91 | -2.04 | 6.12 | 4.33 | 7.91 | 11.18 | -9.74 | 17.17 | 3.47 | 19.04 | 5.06 | 5.13 | -0.66 | 4.98 | 5.44 | 5.16 |
| 54.22 | 52.99 | 53.47 | 54.15 | 54.60 | 54.87 | 53.36 | 56.24 | 54.64 | 54.34 | 56.08 | 52.77 | 52.77 | 52.77 | 52.77 | 52.77 |
| 398.00 | 381.00 | 408.00 | 431.00 | 469.00 | 524.00 | 460.00 | 568.00 | 571.00 | 676.00 | 733.00 | 725.00 | 720.25 | 756.13 | 797.29 | 838.45 |
| 52.00 | 51.00 | 37.00 | 46.00 | 71.00 | 79.00 | 46.00 | 108.00 | 70.00 | 120.00 | 200.00 | 102.00 | 207.00 | 215.00 | 239.00 | 266.00 |
| 7.08 | 7.09 | 4.85 | 5.78 | 8.27 | 8.27 | 5.34 | 10.69 | 6.70 | 9.65 | 15.30 | 7.42 | 15.16 | 15.00 | 15.82 | 16.74 |
| 32.00 | 30.00 | 14.00 | 55.00 | 40.00 | 28.00 | 9.00 | 62.00 | -80.00 | 64.00 | 132.00 | 47.00 | 141.00 | 148.00 | 168.00 | 190.00 |
| -8.57 | -6.25 | -53.33 | 292.86 | -27.27 | -30.00 | -67.86 | 588.89 | -229.03 | -180.00 | 106.25 | -64.39 | 200.00 | 4.96 | 13.51 | 13.10 |
| 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | – |
| 23.08 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 27.76 | 27.88 | 27.99 | 28.30 | 28.90 | 30.50 | 29.94 | 32.77 | 30.93 | 31.50 | 31.11 | 31.03 | 31.03 | 31.03 | 31.03 | 31.03 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Conmed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Conmed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Conmed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Conmed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Conmed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Conmed stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed business model & stock analysis
Conmed SWOT Analysis
Strengths
1. Established Reputation: Conmed Corp has built a strong reputation in the medical device industry over the years.
2. Diversified Product Portfolio: The company offers a wide range of products, including surgical equipment and patient monitoring systems, which reduces its dependence on specific product lines.
3. Global Presence: Conmed has a global footprint, serving customers in various regions, which increases its market reach and potential for growth.
Weaknesses
1. Intense Competition: The medical device industry is highly competitive, and Conmed faces competition from both established players and new market entrants.
2. Reliance on Key Suppliers: The company may face supply chain disruptions or price fluctuations due to its reliance on certain key suppliers.
3. Regulatory Challenges: Complying with regulations and obtaining necessary approvals for new products can be time-consuming and costly for Conmed.
Opportunities
1. Advancements in Medical Technology: The ongoing advancements in medical technology create opportunities for Conmed to develop innovative products and solutions.
2. Growing Aging Population: The increasing global elderly population creates a higher demand for medical devices, providing Conmed with growth opportunities.
3. Emerging Markets: Expanding into emerging markets, such as Asia and Latin America, can help Conmed tap into new customer segments and drive revenue growth.
Threats
1. Economic Volatility: Fluctuations in global economic conditions can impact healthcare spending, which may affect demand for Conmed's products.
2. Stringent Regulatory Environment: Stricter regulations and complex compliance requirements in the medical device industry can pose challenges and increase costs for Conmed.
3. Technological Disruptions: Rapid technological advancements may render certain products or technologies obsolete, requiring Conmed to constantly innovate and stay ahead.
Conmed Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed Segments
Conmed Revenue by Segment (1/3)
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed Revenue by Segment (2/3)
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed Revenue by Segment (3/3)
3 Years
5 Years
10 Years
Max
Details
Conmed Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Conmed Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Conmed historical P/E ratio, EBIT multiple, and P/S ratio
Conmed annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Conmed shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed stock splits
Conmed Dividend History
14 years of dividend payments
Conmed dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Conmed dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Conmed forecasts and price targets in September 2026
Analyst Price Targets 2026Conmed Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/30/2026 | Maintained | Equal Weight | 55 | |
| 7/30/2026 | Maintained | Neutral | 50 | |
| 6/29/2026 | Downgrade | NeutralUnderperform | 64 | |
| 5/18/2026 | Maintained | Neutral | 64 | |
| 5/1/2026 | Maintained | Equal Weight | 55 | |
| 4/30/2026 | Maintained | Neutral | 59 | |
| 3/17/2026 | Downgrade | OverweightNeutral | 50 | |
| 1/29/2026 | Maintained | Equal Weight | 55 | |
| 1/29/2026 | Maintained | Hold | 70 | |
| 12/8/2025 | Maintained | Neutral | 64 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Conmed Earnings Calls
Conmed Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/29/2026 | 1.13USD | - | 344.32 MUSD | - | 2026 Q2 |
| 4/29/2026 | 0.84USD | - | 316.72 MUSD | - | 2026 Q1 |
| 1/28/2026 | 1.35USD | - | 374.13 MUSD | - | 2025 Q4 |
| 4/24/2024 | 0.92USD | - | 318.71 MUSD | - | 2024 Q1 |
| 1/31/2024 | 1.13USD | - | 338.84 MUSD | - | 2023 Q4 |
| 7/25/2023 | 0.82USD | - | 310.28 MUSD | - | 2023 Q2 |
| 5/2/2023 | 0.60USD | - | 272.76 MUSD | - | 2023 Q1 |
| 1/24/2023 | 1.03USD | - | 315.82 MUSD | - | 2022 Q4 |
| 10/26/2022 | 0.77USD | - | 285.05 MUSD | - | 2022 Q3 |
| 7/27/2022 | 0.76USD | - | 278.31 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Conmed stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Conmed shareholder structure
| % | Name |
|---|---|
15.49062% | |
14.18569% | |
11.74112% | |
8.54908% | |
8.24955% | |
6.66608% |
Conmed Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
15.70% | SEC ↗ | |
15.10% | SEC ↗ | |
10.50% | SEC ↗ | |
9.44% | SEC ↗ | |
8.47% | SEC ↗ | |
8.40% | SEC ↗ | |
8.30% | SEC ↗ | |
8.30% | SEC ↗ | |
8.00% | SEC ↗ | |
7.70% | SEC ↗ |
Conmed Executives and Management Board
18 members · avg. age 57 · 22 % women
Mr. Todd Garner (56)
Chief Financial Officer, Executive Vice President - Finance
4.64 M USD
Management
Mr. Patrick Beyer (59)
President, Chief Executive Officer, Director · since 2014
Mr. Peter Shagory (56)
Executive Vice President - Strategy and Corporate Development
Mr. Brent Lalomia (50)
Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations
Ms. Hollie Foust (50)
Executive Vice President, General Counsel and Corporate Secretary
Mr. John Ferrell (57)
Executive Vice President, Human Resources
Mr. Richard Glaze (59)
Chief Information Officer
Board of Directors
Mr. David Bronson (71)
Independent Director
Mr. Brian Concannon (67)
Independent Director
Ms. Laverne Council (63)
Independent Chairman of the Board
Mr. Charles Farkas (73)
Independent Director
Ms. Barbara Schwarzentraub (59)
Independent Director
Mr. Mark Kaye (45)
Independent Director
Conmed Supply Chain
Conmed Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.20 | 0.34 | 0.83 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.32 | -0.39 | -0.12 | ||
| 2 | 0.11 | -0.29 | -0.12 |
Frequently asked questions about Conmed
Conmed Corp is a leading global medical technology company. Its business model revolves around offering a wide range of surgical products and services to healthcare professionals worldwide. The company specializes in the development, manufacturing, and marketing of innovative surgical devices and equipment. With a focus on minimally invasive procedures, Conmed Corp aims to enhance patient outcomes and reduce healthcare costs. By providing solutions for areas such as electrosurgery, endosurgery, and orthopedic surgery, Conmed Corp continues to drive advancements in the medical field. This commitment to delivering high-quality products and advancing medical technologies solidifies its position as a trusted industry leader.
Conmed Corp is primarily active in the medical devices industry.
The main competitors of Conmed Corp in the market include Medtronic, Johnson & Johnson, Stryker Corporation, and Smith & Nephew.
Conmed Corp. is a renowned medical technology company with a rich history and strong background. Founded in 1970, Conmed Corp. has been dedicated to providing innovative surgical solutions and equipment to healthcare professionals worldwide. With its headquarters in Utica, New York, the company has grown to become a leading player in the field of minimally invasive procedures. Conmed Corp. offers a wide range of products, including surgical instruments, endoscopic technologies, and electrosurgical systems, designed to enhance patient outcomes and streamline healthcare processes. With a focus on research and development, Conmed Corp. continues to shape the future of surgical advancements and improve the standard of patient care.
Conmed Corp has achieved several significant milestones throughout its history. The company has successfully established itself as a leading global medical technology provider, specializing in surgical devices and equipment. Conmed Corp has expanded its product portfolio and enhanced its research and development efforts to cater to a wide range of medical specialties. The company has also received numerous accolades and recognition for its innovative solutions and commitment to improving patient outcomes. With its relentless dedication to advancing clinical education and training, Conmed Corp has become a trusted name in the healthcare industry, ensuring enhanced surgical techniques and superior patient care.
Conmed Corp is primarily present in various countries and regions across the globe. The company has a significant presence in the United States, where its headquarters is located. Additionally, Conmed Corp has established a strong market presence in Europe, especially in countries like Germany, France, and the United Kingdom. The company also operates in Asian markets, including China and Japan, and has a growing presence in emerging markets such as India and Brazil. Furthermore, Conmed Corp has a global distribution network, allowing its products and services to reach healthcare facilities worldwide.
Conmed Corp represents a commitment to delivering innovative medical solutions. With a strong corporate philosophy centered around the core values of integrity, quality, and customer focus, the company aims to improve patient outcomes. Conmed Corp is dedicated to maintaining high ethical standards, fostering a culture of continuous improvement, and promoting teamwork and collaboration. By combining cutting-edge technology with a patient-centric approach, Conmed Corp strives to provide healthcare professionals with advanced tools and services that address the evolving needs of the medical community.
Analysts currently set an average price target of 45.08 USD for the Conmed stock (median: 43.86 USD), implying -8.8 % versus the latest price. The consensus is based on 12 analyst ratings.
11 analysts currently rate the Conmed stock: 0 recommend buying, 8 holding and 3 selling. For 2026, analysts expect Conmed to generate revenue of 1.37 B USD and earnings per share of 4.55 USD.
Converted at the current exchange rate, the Conmed share trades at 42.27 EUR (49.12 USD).
The Conmed share (CNMD) is listed on 5 stock exchanges, including: NYSE (CNMD), Frankfurt (EC8.F), München (EC8.MU), Düsseldorf (EC8.DU), SIX (Zürich) (EC8.SW).
Conmed Corporation is a multinational provider of medical devices and instruments used in orthopedics, gastroenterology, endoscopy, laparoscopy, and other medical fields. The company is headquartered in Utica, New York, and operates in more than 30 countries. Conmed has a diverse business segment that focuses on three main categories: Surgical Instruments, Endoscopy, and Electrosurgery. These three divisions offer various products tailored to the specific needs of surgeons and other medical professionals. The Surgical Instruments division includes a wide range of products such as scissors, forceps, needle holders, scalpels, retractors, and other specialized surgical instruments. These instruments are used in a variety of surgical procedures to ensure precision and safety. Endoscopy is an increasingly important field of study in medicine. Here, Conmed offers a range of products such as endoscopes, capsule endoscopes, endoscopic ultrasound probes, and endoscopy accessories. Endoscopes allow doctors to examine internal organs and tissues, reducing the costs and risks associated with traditional surgery. The Electrosurgery division includes products such as generators, active electrodes, monopolar instruments, bipolar instruments, and accessories. Electrosurgery is used in many surgical procedures to cut, coagulate, or remove tissue. Conmed's products enable surgeons to quickly and effectively remove tissue without causing damage to healthy tissue. Conmed's products are used by a variety of medical professionals in various medical fields. The company also provides excellent customer support, ensuring that surgeons and medical professionals can receive assistance at any time. Conmed has introduced the following products on the market: - Hall Zimmer Surgical PowerTools: The system offers electrically powered surgical hand drills, saws, grinders, and other surgical instruments for orthopedics. - Edge Bipolar Clamping System: This is a bipolar instrument system with a universal cable that can be used in many different surgical procedures. - PRO360 Digital Laparoscopy System: A complete endoscopic device system that provides clear, high-resolution imaging for laparoscopy. - EndoRotor Medical Endoscopy Cleaner: This device allows endoscopy systems to be cleaned, disinfected, and sterilized in a simpler and more effective way. Conmed has a robust service and support system aimed at maintaining customer trust and loyalty. Furthermore, Conmed continuously strives to acquire new knowledge and improve its technology to provide surgeons and other medical professionals with the best instruments and products to enhance their success rate and patient outcomes. Overall, Conmed has a first-class business model that helps medical professionals make their work more effective and safer. The company puts its expertise and technology at the service of the healthcare community and is committed to the safety of its customers and their patients. Answer: Conmed Corporation is a multinational provider of medical devices and instruments used in various medical fields such as orthopedics, gastroenterology, and endoscopy. The company focuses on three main categories: Surgical Instruments, Endoscopy, and Electrosurgery. They offer a wide range of products tailored to the specific needs of surgeons and other medical professionals. Conmed aims to provide reliable customer support and continuously improve their technology to enhance the success and safety of medical procedures.
The expected revenue of Conmed is 1.37 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Conmed is 141.28 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Conmed is currently 10.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Conmed stock.
The price-to-sales ratio (P/S) of Conmed is currently 1.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Conmed stock.
The Eulerpool Quality Score for Conmed is 5/10.
The ISIN of Conmed is US2074101013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Conmed is 886793. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Conmed is CNMD. The ticker symbol is used to trade Conmed shares on the stock exchange.
Over the past 12 months, Conmed paid a dividend of 0.60 USD . This corresponds to a dividend yield of about 1.22 %. For the coming 12 months, Conmed is expected to pay a dividend of 0.80 USD.
The current dividend yield of Conmed is 1.22 %.
Conmed pays a dividend, distributed in the months of , , , .
Conmed paid dividends every year for the past 14 years.
For the upcoming 12 months, dividends amounting to 0.80 USD are expected. This corresponds to a dividend yield of 1.63 %.
Conmed is assigned to the 'Health' sector.
To receive the latest dividend of Conmed from amounting to 0.2 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Conmed distributed 0.8 USD as dividends.
The dividends of Conmed are distributed in USD.
Conmed stock
Conmed Peer Group
Conmed Ticker
Conmed FIGI
All fundamentals and in-depth analysis of Conmed
Our stock analysis for Conmed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Conmed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.